Neil Goldstein

2.3k total citations · 1 hit paper
16 papers, 1.4k citations indexed

About

Neil Goldstein is a scholar working on Rheumatology, Hematology and Infectious Diseases. According to data from OpenAlex, Neil Goldstein has authored 16 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Rheumatology, 6 papers in Hematology and 5 papers in Infectious Diseases. Recurrent topics in Neil Goldstein's work include Rheumatoid Arthritis Research and Therapies (7 papers), Autoimmune and Inflammatory Disorders Research (6 papers) and Viral Infections and Outbreaks Research (5 papers). Neil Goldstein is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (7 papers), Autoimmune and Inflammatory Disorders Research (6 papers) and Viral Infections and Outbreaks Research (5 papers). Neil Goldstein collaborates with scholars based in United States, Netherlands and Canada. Neil Goldstein's co-authors include Jürgen Braun, Désirée van der Heijde, C.E.M. Griffiths, Bruce Strober, Peter van de Kerkhof, Vincent Ho, Newman Yeilding, Lisa T. Dooley, Alan Menter and B. Zhou and has published in prestigious journals such as New England Journal of Medicine, PLoS ONE and The Journal of Infectious Diseases.

In The Last Decade

Neil Goldstein

15 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis

2010 644 citations C.E.M. Griffiths, Bruce Strober et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Neil Goldstein

Since Specialization

Citations

This map shows the geographic impact of Neil Goldstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Neil Goldstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Neil Goldstein more than expected).

Fields of papers citing papers by Neil Goldstein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Neil Goldstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Neil Goldstein. The network helps show where Neil Goldstein may publish in the future.

Co-authorship network of co-authors of Neil Goldstein

This figure shows the co-authorship network connecting the top 25 collaborators of Neil Goldstein. A scholar is included among the top collaborators of Neil Goldstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Neil Goldstein. Neil Goldstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Lot-to-lot consistency, immunogenicity, and safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen: A phase 3, randomized, double-blind, placebo-controlled trial 2024 ·Human Vaccines & Immunotherapeutics ·Neil Goldstein, Chelsea McLean, Auguste Gaddah, (unknown), Babajide Keshinro, (unknown), Jenny Hendriks, Kerstin Lühn, Cynthia Robinson, Macaya Douoguih	4
2	First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study 2022 ·PLoS ONE ·Viki Bockstal, Georgi Shukarev, Chelsea McLean, Neil Goldstein, Stephan Bart, Auguste Gaddah, (unknown), Jeroen N. Stoop, Anne Marit de Groot, Maria Grazia Pau, Jenny Hendriks, Stephen C. De Rosa, Kristen W. Cohen, M. Juliana McElrath, Benoît Callendret, Kerstin Lühn, Macaya Douoguih, Cynthia Robinson	19
3	Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen 2021 ·npj Vaccines ·Viki Bockstal, Auguste Gaddah, Neil Goldstein, Georgi Shukarev, Stephan Bart, Kerstin Lühn, Cynthia Robinson, Dickson Anumendem, Maarten Leyssen, Macaya Douoguih	8
4	Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study 2020 ·The Journal of Infectious Diseases ·Neil Goldstein, Viki Bockstal, Stephan Bart, Kerstin Lühn, Cynthia Robinson, Auguste Gaddah, Benoît Callendret, Macaya Douoguih	24
5	SAT0194 Sirukumab integrated safety in rheumatoid arthritis patients: analysis of the sirround phase 3 data 2017 ·Annals of the Rheumatic Diseases ·Daniel Aletaha, Carter Thorne, Michael Schiff, Masayoshi Harigai, R. Bhima Rao, Neil Goldstein, Bin Cheng, Christopher J. Cohen, Benjamin Hsu, Kenneth N. Brown	1
6	Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis 2016 ·The Journal of Rheumatology ·Jonathan Kay, Roy Fleischmann, Edward Keystone, Elizabeth C. Hsia, Benjamin Hsu, Yiying Zhou, Neil Goldstein, Jürgen Braun	29
7	Safety and immunogenicity of heterologous Ad26.ZEBOV and MVA-BN®-Filo prime-boost Ebola vaccines: 6-month follow-up of a Phase I randomized trial in healthy adults 2016 ·Journal of Virus Eradication ·Macaya Douoguih, Neil Goldstein, Stephan Bart, Kerstin Lühn, Wilbert van Duijnhoven, Carla Truyers, Benoît Callendret	1
8	Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study) 2014 ·Annals of the Rheumatic Diseases ·Arthur Kavanaugh, Iain B. McInnes, Philip J. Mease, Gerald G. Krueger, Dafna D. Gladman, Désirée van der Heijde, Yiying Zhou, Jiandong Lu, Jocelyn H. Leu, Neil Goldstein, Anna Beutler	106
9	THU0176 Golimumab 5-Year Safety: an Analysis of Pooled Data from the Long Term Extensions of Randomized, Double-Blind, Placebo-Controlled Studies in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis 2014 ·Annals of the Rheumatic Diseases ·(unknown), R Fleischmann, Edward Keystone, E. C. Hsia, Neil Goldstein, Benjamin Hsu, Yiying Zhou, Jürgen Braun, Arthur Kavanaugh	0
10	Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis 2013 ·Annals of the Rheumatic Diseases ·Jonathan Kay, Roy Fleischmann, Edward Keystone, Elizabeth C. Hsia, Benjamin Hsu, M. Mack, Neil Goldstein, Jürgen Braun, Arthur Kavanaugh	68
11	Vena Cava Filter Fracture With Migration to the Pulmonary Artery 2012 ·The Annals of Thoracic Surgery ·David A. Hill, Neil Goldstein, Elbert Kuo	2
12	LONG-TERM RADIOGRAPHIC OUTCOME IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH GOLIMUMAB : 104 WEEK RESULTS FROM THE GO-REVEAL STUDY 2012 ·Data Archiving and Networked Services (DANS) ·Arthur Kavanaugh, (unknown), (unknown), D. Gladman, Philip J. Mease, Iain B. McInnes, (unknown), W. Xu, Neil Goldstein, Anna Beutler	4
13	Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis breakdown → 2010 ·New England Journal of Medicine ·C.E.M. Griffiths, Bruce Strober, Peter van de Kerkhof, Vincent Ho, (unknown), Newman Yeilding, Cynthia Guzzo, Yichuan Xia, B. Zhou, Shu Li, Lisa T. Dooley, Neil Goldstein, Alan Menter	644
14	Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis 2008 ·Arthritis & Rheumatism ·Désirée van der Heijde, Robert Landewé, Xenofon Baraliakos, Harry Houben, Astrid van Tubergen, Paul Williamson, Weichun Xu, Daniel Baker, Neil Goldstein, Jürgen Braun	380
15	Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two‐year period 2008 ·Arthritis Care & Research ·Jürgen Braun, Atul Deodhar, Ben A. C. Dijkmans, Piet Geusens, Joachim Sieper, Paul Williamson, Weichun Xu, Sudha Visvanathan, Daniel Baker, Neil Goldstein, Désirée van der Heijde	87
16	Efficacy of oral WIN 54954 for prophylaxis of experimental rhinovirus infection 1993 ·Antimicrobial Agents and Chemotherapy ·Ronald B. Turner, Frank J. Dutko, Neil Goldstein, G. Lockwood, Frederick G. Hayden	46

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact